Skip to main content

Advertisement

Log in

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European countries. This paper presents the estimated budget impact of the introduction of biosimilar infliximab in RA over a 3-year time period in six selected countries, namely Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. A prevalence-based model was constructed for budget impact analysis. Two scenarios were compared to the reference scenario (RSc) where no biosimilar infliximab is available: biosimilar scenario 1 (BSc1), where interchanging the originator infliximab with biosimilar infliximab is disallowed, and only patients who start new biological therapy are allowed to use biosimilar infliximab; as well as biosimilar scenario 2 (BSc2), where interchanging the originator infliximab with biosimilar infliximab is allowed, and 80 % of patients treated with originator infliximab are interchanged to biosimilar infliximab. Compared to the RSc, the net savings are estimated to be €15.3 or €20.8 M in BSc1 and BSc2, respectively, over the 3 years. If budget savings were spent on reimbursement of additional biosimilar infliximab treatment, approximately 1,200 or 1,800 more patients could be treated in the six countries within 3 years in the two biosimilar scenarios, respectively. The actual saving is most sensitive to the assumption of the acquisition cost of the biosimilar drug and to the initial number of patients treated with biological therapy. The study focused on one indication (RA) and demonstrated that the introduction of biosimilar infliximab can lead to substantial budget savings in health care budgets. Further savings are expected for other indications where biosimilar medicines are implemented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Sokka, T., Kautiainen, H., Pincus, T., Verstappen, S.M., Aggarwal, A., Alten, R., Andersone, D., Badsha, H., Baecklund, E., Belmonte, M., Craig-Muller, J., da Mota, L.M., Dimic, A., Fathi, N.A., Ferraccioli, G., Fukuda, W., Geher, P., Gogus, F., Hajjaj-Hassouni, N., Hamoud, H., Haugeberg, G., Henrohn, D., Horslev-Petersen, K., Ionescu, R., Karateew, D., Kuuse, R., Laurindo, I.M., Lazovskis, J., Luukkainen, R., Mofti, A., Murphy, E., Nakajima, A., Oyoo, O., Pandya, S.C., Pohl, C., Predeteanu, D., Rexhepi, M., Rexhepi, S., Sharma, B., Shono, E., Sibilia, J., Sierakowski, S., Skopouli, F.N., Stropuviene, S., Toloza, S., Valter, I., Woolf, A., Yamanaka, H.: Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res. Ther. 12(2), R42 (2010). doi:10.1186/ar2951

    Article  PubMed Central  PubMed  Google Scholar 

  2. Laires, P.A., Exposto, F., Mesquita, R., Martins, A.P., Cunha-Miranda, L., Fonseca, J.E.: Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur. J. Health Econ. 14(6), 875–885 (2013). doi:10.1007/s10198-012-0432-5

    Article  CAS  PubMed  Google Scholar 

  3. Mauskopf, J.A., Sullivan, S.D., Annemans, L., Caro, J., Mullins, C.D., Nuijten, M., Orlewska, E., Watkins, J., Trueman, P.: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis. Value Health 10(5), 336–347 (2007)

    Article  PubMed  Google Scholar 

  4. Orlewska, E., Gulacsi, L.: Budget-impact analyses: a critical review of published studies. PharmacoEconomics 27(10), 807–827 (2009)

    PubMed  Google Scholar 

  5. van de Vooren, K., Duranti, S., Curto, A., Garattini, L.: A critical systematic review of budget impact analyses on drugs in the EU countries. Appl. Health Econ. Health Policy 12(1), 33–40 (2014). doi:10.1007/s40258-013-0064-7

    PubMed  Google Scholar 

  6. Launois, R., Payet, S., Saidenberg-Kermanac’h, N., Francesconi, C., Franca, L.R., Boissier, M.C.: Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 75(6), 688–695 (2008). doi:10.1016/j.jbspin.2008.04.012

    PubMed  Google Scholar 

  7. Sorensen, J., Andersen, L.S.: The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. PharmacoEconomics 23(3), 289–298 (2005)

    CAS  PubMed  Google Scholar 

  8. Tóthfalusi, L., Endrényi, L., Chow, S.-C.: Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur. J. Health Econ. (2014). doi:10.1007/s10198-014-0589-1

  9. Péntek, M., Poór, G., Wiland, P., Martina, O., Brzosko, M., Codrenau, C., Brodszky, N., Gulácsi, L.: Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur. J. Health Econ. (2014). doi:10.1007/s10198-014-0592-6

  10. Laki, J., Székelyné Mónok, G.: Biological treatments—analysis by the NHIFA. http://www.oep.hu/pls/portal/url/ITEM/C97D04DF65C8B4CEE040A8C0CB324B94. (2012)

  11. Koncz, T., Pentek, M., Brodszky, V., Érsek, K., Orlevska, E., Gulacsi, L.: Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin. Biol. Ther. 9, 1367–1378 (2010)

    Google Scholar 

  12. Laki, J., Monok, G., Palosi, M., Gajdacsi, J.Z.: Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin. Biol. Ther. 13(3), 327–337 (2013). doi:10.1517/14712598.2013.735654

    PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by an unrestricted grant from EGIS Pharmaceuticals and Center for Public Affairs Studies Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Valentin Brodszky.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brodszky, V., Baji, P., Balogh, O. et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 15 (Suppl 1), 65–71 (2014). https://doi.org/10.1007/s10198-014-0595-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-014-0595-3

Keywords

JEL Classification

Navigation